Dengue vaccine gets a makeover: new formula tested in phase 3 trial
NCT ID NCT07047521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new formulation of Takeda's dengue vaccine (TDV) works as well as the current approved version. About 496 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. The main goal is to compare immune responses between the two formulations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tetravalent Dengue Vaccine (TDV, also known as TAK-003)
What this could lead to
If successful, this could confirm that the new formulation works as well as the approved vaccine, potentially simplifying manufacturing or distribution.
What could go wrong
This is a non-endemic area study in healthy adults, so results may not fully predict effectiveness in real-world dengue-endemic regions. The trial is also relatively small (496 participants).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emeritus Research Camberwell (Melbourne)
Camberwell, Victoria, 3124, Australia
-
Emeritus Research Sydney
Botany, New South Wales, 2019, Australia
-
Paratus Clinical Research Central Coast
Kanwal, New South Wales, 2259, Australia
-
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, 2150, Australia
-
Veritus Research
Bayswater, Victoria, 3153, Australia